• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

CARMUSTINE Drug Record

  • Summary
  • Interactions
  • Claims
  • CARMUSTINE chembl:CHEMBL513 ApprovedAntineoplasticImmunotherapy

    Alternate Names:

    BCNU
    GLIADEL
    SRI-1720
    CARMUSTINE
    NSC-409962
    FDA-0345
    DTI-015
    SK-27702
    BICNU
    CARUSTINE®
    BISCHLOROETHYL NITROSOUREA
    N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA
    BICNU®
    BIS-CHLOROETHYLNITROSOUREA
    CARMUSTINUM
    CARMUSTINA
    BICNU (TN)
    pubchem.compound:2578
    drugbank:00262
    chembl:CHEMBL513
    rxcui:2105
    chemidplus:154-93-8

    Drug Info:

    Drug Class antineoplastic agents
    Year of Approval 1977
    FDA Approval approved
    Drug Class Small Molecule
    Drug Indications antineoplastic agent
    (5 More Sources)

    Publications:

    Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol
    Go et al., 1997, Cisplatin but not BCNU inhibits urokinase-type plasminogen activator levels in human glioblastoma cell lines in vitro., Clin. Exp. Metastasis
    Gomez-Manzano et al., 2001, Adenovirally-mediated transfer of E2F-1 potentiates chemosensitivity of human glioma cells to temozolomide and BCNU., Int. J. Oncol.
    Powell et al., 1987, Effect of inhibition of glutathione reductase by carmustine on central nervous system oxygen toxicity., J. Pharmacol. Exp. Ther.
    Doroshenko et al., 2004, The glutathione reductase inhibitor carmustine induces an influx of Ca2+ in PC12 cells., Eur. J. Pharmacol.
    Vallyathan et al., 1992, Enhanced generation of free radicals from phagocytes induced by mineral dusts., Am. J. Respir. Cell Mol. Biol.
    Jopperi-Davis et al., 2004, Compartmental inhibition of hepatic glutathione reductase activities by 1,3-bis(2-chloroethyl)-N-nitrosourea (BCNU) in Sprague-Dawley and Fischer-344 rats., Toxicol. Lett.
    Akella et al., Pyridine nucleotide flux and glutathione oxidation in the cultured rat conceptus., Reprod. Toxicol.
    Kirsch et al., 2002, Accumulation of glutathione disulfide mediates NF-kappaB activation during immune stimulation with CpG DNA., Antisense Nucleic Acid Drug Dev.
    Puglia et al., 1984, Inhibition of cellular antioxidants: a possible mechanism of toxic cell injury., Environ. Health Perspect.
    Brodie et al., 1992, Glutathione disulfide reduction in tumor mitochondria after t-butyl hydroperoxide treatment., Chem. Biol. Interact.
    Esteller et al., 2000, Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents., N. Engl. J. Med.
    Sagone AL Jr et al., 1979, The effect of BCNU and adriamycin on normal and G6PD deficient erythrocytes., Am J Hematol
  • CARMUSTINE   GSR

    Interaction Score: 4.12

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name polifeprosan 20/carmustine,Gliadel
    Novel drug target Established target
    Mechanism of Interaction Glutathione reductase inhibitor

    PMIDs:
    3806383 15321730 1312851 15104113 10378469 12477282 6094175 1394620


    Sources:
    TdgClinicalTrial ChemblInteractions TEND

  • CARMUSTINE   E2F1

    Interaction Score: 0.7

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    11445852


    Sources:
    NCI

  • CARMUSTINE   MGMT

    Interaction Score: 0.59

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    11070098


    Sources:
    CIViC

  • CARMUSTINE   PLAU

    Interaction Score: 0.43

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    9219734


    Sources:
    NCI

  • CARMUSTINE   G6PD

    Interaction Score: 0.16

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    539595


    Sources:
    PharmGKB

  • CARMUSTINE   CYP2C9

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC

  • CARMUSTINE   CYP2C19

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC

  • CARMUSTINE   CYP1A2

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC

  • CARMUSTINE   CYP2D6

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC

  • CARMUSTINE   ALDH1A1

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • CARMUSTINE   CYP3A4

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC

  • TEND: CARMUSTINE

    • Version: 01-August-2011

    Alternate Names:
    CARMUSTINE Primary Drug Name

    Drug Info:
    Year of Approval 1977
    Drug Class antineoplastic agents

    Publications:

  • TdgClinicalTrial: CARMUSTINE

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications antineoplastic agent
    Drug Class Small Molecule
    FDA Approval approved

    Publications:

  • NCI: BCNU

    • Version: 14-September-2017

    Alternate Names:
    C349 NCI drug code

    Drug Info:

    Publications:
    Go et al., 1997, Cisplatin but not BCNU inhibits urokinase-type plasminogen activator levels in human glioblastoma cell lines in vitro., Clin. Exp. Metastasis
    Gomez-Manzano et al., 2001, Adenovirally-mediated transfer of E2F-1 potentiates chemosensitivity of human glioma cells to temozolomide and BCNU., Int. J. Oncol.

  • DTC: CARMUSTINE

    • Version: 02-September-2020

    Alternate Names:
    CHEMBL513 ChEMBL Drug ID

    Drug Info:

    Publications:
    Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol

  • PharmGKB: carmustine

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Sagone AL Jr et al., 1979, The effect of BCNU and adriamycin on normal and G6PD deficient erythrocytes., Am J Hematol

  • CIViC: CARMUSTINE

    • Version: 14-September-2020

    Alternate Names:

    Drug Info:

    Publications:
    Esteller et al., 2000, Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents., N. Engl. J. Med.

  • TTD: DTI-015

    • Version: 2020.06.01

    Alternate Names:
    D01OXI TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL513

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • ChemblInteractions: CHEMBL513

    • Version: chembl_23

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21